Multi-Market Submission Strategy Including KSA
Leveraging EU MDR documentation
Manufacturers with existing CE marking under EU MDR are best positioned to enter the Saudi market because:
- SFDA classification rules are identical to EU MDR Annex VIII
- The technical file structure (Annex 3 of MDS-REQ 1) mirrors EU MDR technical documentation
- Essential Principles align with EU MDR GSPR (Annex I)
- Risk management, clinical evaluation, and labelling requirements follow the same international standards
While CE marking does not replace MDMA, manufacturers can reuse most EU technical documentation with adaptations for SFDA-specific requirements (DoC template, AR details, Arabic labelling where needed).
Recommended sequencing for multi-market entry
- EU MDR / FDA — establish core technical file and clinical evidence
- Saudi Arabia (SFDA) — adapt technical file to MDS-REQ 1, appoint AR, apply via GHAD
- UAE, Kuwait, Bahrain — leverage SFDA registration as regional base; submit to each authority
- Other GCC markets — coordinate with local distributors/ARs in each country
Key adaptations required for SFDA vs EU MDR
| Element | EU MDR | SFDA adaptation needed |
|---|---|---|
| DoC template | Own format | Must use SFDA Annex 14 template |
| AR on labels | EU AR name/address | Saudi AR name/address |
| Language | Local EU language + English | English + Arabic for home-use |
| Submission portal | EUDAMED | GHAD |
| Certificate holder | Manufacturer | AR |